+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing



Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing



Clinical Infectious Diseases 56(11): 1659-1666



A tropism test is required before administration of the antiretroviral drug maraviroc. However, plasma RNA testing is not possible in patients with undetectable plasma viral loads. Here we assess genotypic testing of cellular human immunodeficiency virus (HIV) DNA from peripheral blood mononuclear cells (PBMCs) to predict virologic responses in treatment-experienced patients beginning maraviroc-containing regimens. PBMC samples from 181 maraviroc recipients at study entry in MOTIVATE or A4001029 (51% R5 by original Trofile). The V3 loop was amplified in triplicate from cellular HIV DNA, and matching plasma RNA (n = 156). Sequencing was performed using standard population-based methods and next-generation deep sequencing, with tropism assessment as previously defined. Genotypic DNA-based tropism testing from the cellular compartment had 78%-81% sensitivity relative to RNA-based Trofile at the same time point. Cell-based genotypic tropism methods and plasma-based phenotypic and genotypic methods were predictive of virologic response. However, when classifications were discordant, the outcomes favored the plasma predictions over the DNA ones. Genotypic determination of HIV tropism can be performed using cell-derived viral DNA, and is a predictor of virologic success on maraviroc in therapy-experienced patients. However, the PBMC compartment appears to be a suboptimal predictor compared to plasma.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056795419

Download citation: RISBibTeXText

PMID: 23429552

DOI: 10.1093/cid/cit105


Related references

Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial. Journal of Acquired Immune Deficiency Syndromes 61(3): 279-286, 2012

Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods. Antimicrobial Agents and ChemoTherapy 56(3): 1202-1207, 2012

Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study. Journal of Acquired Immune Deficiency Syndromes 64(2): 167-173, 2013

High Virologic Failure Rates with Maraviroc-Based Salvage Regimens Among Indian Patients: A Preliminary Analysis-Maraviroc Effectiveness in HIV-1 Subtype C. Journal of the International Association of Providers of Aids Care 17: 2325958218759211, 2018

Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc. Journal of Virology 92(11):, 2018

Does ultra-deep-sequencing in HCV patients treated with boceprevir/telaprevir-based therapy provide an added value in comparison to standard population-sequencing in the detection of resistance?. Digestive and Liver Disease 46: E47-E48, 2014

Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. Clinical Infectious Diseases 53(7): 732-742, 2011

A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patients. Plos one 7(9): E46334, 2012

Maraviroc and CD4+ cell count recovery in patients with virologic suppression and blunted CD4+ cell response. Aids 23(7): 869, 2009

Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. Journal of Infectious Diseases 203(2): 237-245, 2011

Does sequencing the PKRBD of hepatitis C virus NS5A predict therapeutic response to combination therapy in an Australian population?. Journal of Gastroenterology and Hepatology 19(5): 551-557, 2004

'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing. Journal of Antimicrobial ChemoTherapy 66(11): 2615-2623, 2011

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc. Plos one 10(6): E0127816, 2015

Ultra-deep sequencing reveals hidden HIV-1 minority lineages and shifts of viral population between the main cellular reservoirs of the infection after therapy interruption. Journal of Medical Virology 84(6): 839-844, 2012

Virological response to short-course maraviroc monotherapy does not predict viral tropism in HIV-1-infected treatment-naive patients. Journal of Antimicrobial ChemoTherapy 69(7): 1916-1919, 2014